Similarly, a nationwide retrospective cohort study showed that SGLT2 inhibitors, compared with dipeptidyl peptidase-4 inhibitors, were associated with a lower risk of coronary revascularization, combined renal outcomes, and all-cause mortality in T2DM patients after PCI (41). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.